Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 3, 2013, Pages 333-340

  Benkov, Keith ^a   Lu, Ying ^b   Patel, Ashish ^c   Rahhal, Riad ^d   Russell, Gary ^e   Teitelbaum, Jonathan ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Children's Medical Center   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

6 mercaptopurine; 6 methylmercaptopurine; 6 thioguanine nucleotides; azathioprine; Crohn disease; inflammatory bowel disease; thiopurine; thiopurine methyltransferase; ulcerative colitis

Indexed keywords

6 METHYLTHIOINOSINE; ALLOPURINOL; AZATHIOPRINE; CAPTOPRIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; PLACEBO; PREDNISONE; THIOGUANINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE;

BLOOD CELL COUNT; BONE MARROW SUPPRESSION; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DRUG DETERMINATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTERITIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEMOLYSIS; HOMOZYGOTE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; MEDICAL SOCIETY; PANCREATITIS; PANCYTOPENIA; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTRANSFORMATION; COLITIS, ULCERATIVE; CONSENSUS; CROHN DISEASE; DRUG INTERACTIONS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; PRACTICE GUIDELINES AS TOPIC; PURINES; SOCIETIES, SCIENTIFIC; SULFHYDRYL COMPOUNDS; THIONUCLEOSIDES;

EID: 84874948156     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182844705     Document Type: Review

References (93)

1. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-Term, randomized, double-blind study. N Engl J Med 1980;302:981-7
2. Lennard L. Assay of 6-Thioinosinic acid and 6-Thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987;423:169-78
3. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996; 39:401-6
4. Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(Suppl 1):S2-5
5. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010:CD000545
6. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009:CD000067
7. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902
8. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007:CD000478
9. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:944-7
10. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: A controlled evaluation. Gastroenterology 1974;66: 916-22
11. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8
12. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72
13. Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005;11:685-95
14. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: Prevention and diagnosis. Gut 2008;57:549-58
15. Lichtenstein GR, Abreu MT, Cohen R, et al., American Gastroenterological AssociationAmerican Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:940-87
16. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: Short- And long-Term toxicity. Ann Intern Med 1989;111:641-9
17. Warman JI, Korelitz BI, Fleisher MR, et al. Cumulative experience with short- And long-Term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003; 37:220-5
18. Leveque N, Brixi-Benmansour H, Reig T, et al. Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. J Med Virol 2010;82:1694-700
19. Biank VF, Sheth MK, Talano J, et al. Association of Crohn's disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr 2011;159:808-12
20. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5
21. Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: Analysis of a large single-center cohort. Inflamm Bowel Dis 2012;18:838-43
22. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41
23. Siegel CA, Finlayson SR, Sands BE, et al. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10:46-51
24. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:593-9
25. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005;100:2239-47
26. Garat A, Cauffiez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol 2008;76:404-15
27. Krynetski EY, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A 1995;92:949-53
28. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702
29. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73
30. Schaeffeler E, Stanulla M, Greil J, et al. A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. Leukemia 2003;17:1422-4
31. Hamdan-Khalil R, Gala JL, Allorge D, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT-16 and TPMT-19. Biochem Pharmacol 2005;69:525-9
32. Lindqvist M, Haglund S, Almer S, et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 2004;14:261-5
33. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407-17
34. Schaeffeler E, Eichelbaum M, ReinischW, et al. Three novel thiopurine S-methyltransferase allelic variants (TPMT-20, -21, -22) - Association with decreased enzyme function. Hum Mutat 2006;27:976
35. Salavaggione OE, Wang L, Wiepert M, et al. Thiopurine S-methyltransferase pharmacogenetics: Variant allele functional and comparative genomics. Pharmacogenet Genomics 2005;15:801-15
36. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62
37. Ford LT, Cooper SC, Lewis MJ, et al. Reference intervals for thiopurine S-methyltransferase activity in red blood cells using 6-Thioguanine as substrate and rapid non-extraction liquid chromatography. Ann Clin Biochem 2004;41 (Pt 4):303-8
38. Holme SA, Duley JA, Sanderson J, et al. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM 2002; 95:439-44
39. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5
40. Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-7
41. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15
42. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003;52:140-2
43. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30
44. Cheung ST, Allan RN. Mistaken identity: Misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol 2003;15:1245-7
45. Rahhal RM, Bishop WP. Initial clinical experience with allopurinolthiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1678-82
46. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-Treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117:527-35
47. Giverhaug T, Klemetsdal B, Lysaa R, et al. Intraindividual variability in red blood cell thiopurine methyltransferase activity. Eur J Clin Pharmacol 1996;50:217-20
48. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine- related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75
49. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br JClinPharmacol 1995;39:456-9
50. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39
51. Allan PW, Bennett LL Jr. 6-Methylthioguanylic acid, a metabolite of 6-Thioguanine. Biochem Pharmacol 1971;20:847-52
52. Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: A mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 2005;312:537-45
53. Marinaki AM, Sumi S, Arenas M, et al. Allele frequency of inosine triphosphate pyrophosphatase gene polymorphisms in a Japanese population. Nucleosides Nucleotides Nucleic Acids 2004;23:1399-401
54. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14:181-7
55. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: Quantitation of red blood cell 6-Thioguanine nucleotide, 6-Thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90
56. Vikingsson S, Carlsson B, Almer SH, et al. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther Drug Monit 2009;31:345-50
57. de Graaf P, Vos RM, de Boer NH, et al. Limited stability of thiopurine metabolites in blood samples: Relevant in research and clinical practise. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1437-42
58. Vikingsson S, Carlsson B, Almer S, et al. How should thiopurine treatment be monitored? - Methodological aspects. Nucleosides Nucleotides Nucleic Acids 2010;29:278-83
59. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-Thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6
60. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13
61. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003;3(Suppl 1):S30-8
62. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol 2000;95:1139-46
63. Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-Tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005;21:829-39
64. Grossman AB, Noble AJ, Mamula P, et al. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008; 14:750-5
65. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70
66. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in crohn disease. Scand J Gastroenterol 2001;36:71-6
67. Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:450-4
68. Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011;17: 1301-7
69. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-Thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-Analysis. Gastroenterology 2006;130:1047-53
70. Waljee AK, Joyce JC,Wang S, et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol 2010;8:143-50
71. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: Correlation with treatment efficacy. Aliment Pharmacol Ther 2000;14:1009-14
72. Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302
73. Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005; 22:605-11
74. Lowry PW, Franklin CL,Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001;49:656-64
75. de Boer NK, Derijks LJ, Keizer-Garritsen JJ, et al. Extended thiopurine metabolite assessment during 6-Thioguanine therapy for immunomodulation in Crohn's disease. J Clin Pharmacol 2007;47:187-91
76. Hande S,Wilson-Rich N, Bousvaros A, et al. 5-Aminosalicylate therapy is associated with higher 6-Thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006;12:251-7
77. Stocco G, Martelossi S, Malusa' N, et al. Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: Possible causes of ulcerative colitis relapse. Dig Dis Sci 2008;53:3246-9
78. Xin H, Fischer C, Schwab M, et al. Effects of aminosalicylates on thiopurine S-methyltransferase activity: An ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21: 1105-9
79. Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:79-85
80. Daperno M, Sostegni R, Canaparo R, et al. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2009;30:843-53
81. Andrews JM, Travis SP, Gibson PR, et al. Systematic review: Does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 2009;29:459-69
82. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5:209-14
83. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005;22:441-6
84. Leung Y, Sparrow MP, Schwartz M, et al. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 2009;3:162-7
85. Gardiner SJ, Gearry RB, Burt MJ, et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol 2011;26:49-54
86. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:640-7
87. Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: A review of four cases and the literature. Can J Gastroenterol 2008;22:181-5
88. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:973-83
89. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: Adverse events and clinical benefit in IBD. J Crohns Colitis 2010;4:444-9
90. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine and azathioprine in adult IBD patients. Am J Gastroenterol 2007;102:2488-94
91. Mardini HE, Arnold GL. Utility of measuring 6-methylmercaptopurine and 6-Thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 2003;36:390-5
92. Lichenstein GH. Monitoring 6-mercaptopurine/azathioprine metabolite levels. Am J Gastroenterol 2007;102:S14-7
93. Janssens PM. Managing the demand for laboratory testing: Options and opportunities. Clin Chim Acta 2010;411:1596-602